Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- NCI paylines to drop to 9th percentile amid CRs and uncertainty
- Brian Druker steps down as CEO of OHSU Knight Cancer Center
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - An NCI initiative focuses on early-onset cancers
- An elephant in the room: Grief in young adults with cancer
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities